The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: From research to therapy

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 125-133

  Sagiv, Eyal ^a   Arber, Nadir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer treatment; CD24; GI cancer; Monoclonal antibody; Oncogene; P selectin; Signal transduction; Tumor stem cell

Indexed keywords

C 20 ANTIBODY; CD24 ANTIGEN; ML 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD24; PADGEM PROTEIN; SWA 11; TUMOR MARKER;

AMINO ACID SUBSTITUTION; AUTOIMMUNE DISEASE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DNA MICROARRAY; DRUG RESEARCH; DRUG SYNTHESIS; EARLY DIAGNOSIS; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC HETEROGENEITY; GENETIC RISK; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PANCREAS CANCER; PHENOTYPE; POPULATION GENETICS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 49149110192     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.125     Document Type: Review

References (69)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
2. Bodmer WF, Bailey CJ, Bodmer J et al. Localisation of the gene for familial adenomatous polyposis on chromosome 5. Nature 328, 614-616 (1987).
3. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis ofAPC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 340, 626-630 (1992).
4. Jeong S, Lee DH, Lee JI et al. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J. Gastroenterol. 11, 6765-6769 (2005).
5. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer glycodynamics and functions. EMBO Rep. 7(6), 599-604 (2006).
6. Kay R, Takei F, Humphries RK. Expression cloning of a cDNA encoding M1/ 69-J11d heat-stable antigens. J. Immunol. 145, 1952-1959 (1990).
7. Kristiansen G, Sammar M, Altevogt P. Tumor biological aspects of CD24, a mucin-like adhesion molecule. J. Molecular Histology 35, 255-262 (2004).
8. Ohl C, Albach C, Altevogt P, Schmitz B. N-glycosylation patterns of HSA/CD24 from di&rent cell lines and brain homogenats: a comparison. Biochimie 85, 565-573 (2003).
9. Wang L, Lin S, Rammohan KW et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet. 3, E49 (2007).
10. Zarn JA, Jackson DG, Bell MV et al. The small cell lung cancer antigen cluster-4 and die leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21. Cytogenet. Cell Genet. 70, 119-125 (1995).
11. Hough MR, Rosten PM, Sexton TL, Kay R, Humphries RK. Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics 22, 154-161 (1994).
12. Pass MK, Quintini G, Zarn JA, Zimmermann SM, Sigrist JA, Stahel RA. The 5′-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int. J. Cancer 78, 496-502 (1998).
13. Zhou Q, Rammohan K, Lin S et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc. Natl Acad Sci. USA 100, 15041-15046 (2003).
14. Sánchez E, Abelson AK, Sabio JM et al. Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 56, 3080-3086 (2007).
15. Wawrzynczak EJ, Derbyshire EJ, Henry RV et al. Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognizing a human small cell lung cancer antigen. Br. J. Cancer 62, 410-414 (1990).
16. Nielsen PJ, Lorenz B, Muller AM et al. Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Blood 89, 1058-1067 (1997).
17. Chappel MS, Hough MR, Mittel A, Takei F, Kay R, Humphries RK. Cross-linking the murine heat-stable antigen induces apoptosis in B cell precursors and suppresses the anti-CD40-induced proliferation of mature resting B lymphocytes. J. Exp. Med. 184, 1638-1649 (1996).
18. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of Pro-B and Pre-Pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173, 1213-1225 (1991).
19. hi splenic B cells are an immature developmental intermediate in the production of long-lived bone marrow-derived B cells. J. Immunol. 151, 4431-4444 (1993).
20. + effector and memory T cells by dendritic cells in vivo. Immunol. Lett. 94(3), 229-237 (2004).
21. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007).
22. Cram DS, McIntosh A, Oxbrow L, Johnston AM, DcAizpurua HJ. Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. Differentiation 64, 237-246 (1999).
23. Poncet C, Frances V, Gristina R et al. CD24, a GPI-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol. 91, 400-408 (1996).
24. Knowles DM, Dodson LD, Raab R, Mittler RS, Talle MA, Goldstein G. The application of monoclonal antibodies to the characterization and diagnosis of lymphoid neoplasms: a review of recent studies. Diagn. Immunol. 1, 142-149 (1983).
25. Foa F, Migone N, Fierro MT et al. Genotypic characterization of common acute lymphoblastic leukemia may improve the phenotypic classification. Exp. Hematol. 15, 942-945 (1987).
26. Valet G, Repp R, Link H, Ehninger A, Gramatzki MM. Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry 53, 4-10 (2003).
27. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am. J. Pathol. 137, 895-905 (1990).
28. Fogel M, Friederichs J, Zeller Y et al. CD24 is a marker for human breast carcinoma. Cancer Lett. 143, 87-94 (1999).
29. Kristiansen G, Winzer, KJ, Mayordomo E et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906-4913 (2003).
30. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 98, 1176-1181 (2001).
31. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 161, 1215-1221 (2002).
32. Liu AY, True LD. Characterization of prostate cell types by CD cell surface molecules. Am. J. Pathol. 160, 37-43 (2002).
33. Kristiansen G, Pilarsky C, Pervan J et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58, 183-192 (2004).
34. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer 88, 231-236 (2003).
35. Deichmann M, Kurzen H, Egner U, Altevogt P, Hartschuh W. Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). J. Cutan. Pathol. 30, 363-368 (2003).
36. Karahan N, Guney M, Oral B, Kapucuoglu N, Mungan T. CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 27, 500-504 (2006).
37. Lim SC. CD24 and human carcinoma: tumor biological aspects. Biomed. Pharmacother. 59, 351-354 (2005).
38. Sagiv E, Memeo L, Karin A et al. CD24 is a new oncogene, early at the multi-step process of colorectal cancer carcinogenesis. Gastroenterology 131, 630-639 (2006).
39. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res. 55, 4717-4721 (1995).
40. Nestl A, Von Stein OD, Zatloukal K et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 61, 1569-1577 (2001).
41. Weichert W, Denkert C, Burkhardt M et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin. Cancer Res. 11, 6574-6581 (2005).
42. Chou YY, Jeng YM, Lee TT et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann. Surg. Oncol. 14, 2748-2758 (2007).
43. Choi YL, Kim SH, Shin YK et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol. Oncol. 97, 379-386 (2005).
44. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62, 2890-2896 (2002).
45. Jacob J, Bellach J, Grutzmann R et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4, 454-460 (2004).
46. Sagiv E, Kazanov D, Arber N. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed. Pharmacother. 60, 280-284 (2006).
47. Aigner S, Ruppert M, Hubbe M et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int. Immunol. 7, 1557-1565 (2005).
48. Sammar M, Aigner S, Hubbe M et al. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int. Immunol. 6, 1027-1036 (1994).
49. Aigner S, Sthoeger ZM, Fogel M et al. CD24, a mucintype glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89, 3385-3395 (1997).
50. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins - potential pharmacological targets? Drug Discov. Today. 11, 1034-1040 (2006).
51. Kim YJ, Borsig L, Varki NM, Varki. A P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 95, 9325-9330 (1998).
52. Kleene R, Yang H, Kutsche M, Schachner M. The neural recognition molecule L1 is a sialic acid-binding lectin for CD24, which induces promotion and inhibition of neurite outgrowth. J. Biol. Chem. 276, 21656-21663 (2001).
53. Gavert N, Conacci-Sorrell M, Gast D et al. L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol. 168, 633-642 (2005).
54. Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA. Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line Biochem Biophys Res Commun 225, 384-391 (1996).
55. Kadmon G, von Bohlen und Halbach F, Schachner M, Altevogt P. Differential, LFA-1-sensitive effects of antibodies to nectadrin, the heat-stable antigen, on B lymphoblast aggregation and signal transduction. Biochem. Biophys. Res. Commun. 198, 1209-1215 (1994).
56. Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell Sci. 119, 314-325 (2006).
57. Baumann P, Cremers N, Kroese F et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 65, 10783-10793 (2005).
58. Smith SC, Oxford G, Wu Z et al. The metastasis-associated gene CD24 is regulated by Ral GTPasc and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 66, 1917-1922 (2006).
59. Runz S, Mierke CT, Joumaa S, Behrens J, Fabry B, Altevogt P. CD24 induces localization of β1 integrin to lipid raft domains. Biochem Biophys Res Commun. 365, 35-41 (2008).
60. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis inhuman B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J. Immunol. 166, 5567-5577 (2001).
61. Taguchi T, Kiyokawa N, Mimori K et al. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J. Immunol. 170, 252-260 (2003).
62. Jung KC, Park WS, Kim HJ et al. TCR-independent and caspase-independent apoptosis of murine thymocytes by CD24 cross-linking. J. Immunol. 172, 795-802 (2004).
63. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
64. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988 (2003).
65. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2004).
66. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON Isolation and functional characterization of routine prostate stem cells. Proc. Natl. Acad. Sci. USA 104, 181-186 (2007).
67. + breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98, 1777-1785 (2006).
68. Stingl J, Eirew P, Ricketson I et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006).
69. Berman DM, Karhadkar SS, Maitra A et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851 (2007).